- Where are we going wrong? - Contrasting the scale-up manufacturing of adult cells versus pluripotent cells, and analysing the advantages and disadvantages of both
- A look into novel technologies for the reproducible manufacturing of 1 st & 2 nd generation, highly-identified, purified products derived from pluripotent stem cells
- Case Study - the unique phenotype of pluripotent-stem-cell-derived cells that could improve the process of tissue repair
BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.